Pact Pharma Stock

pactpharma.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $354.6MM

PACT Pharma clinical stage biotechnology company developing personalized adoptive T cell therapies for the eradication of solid tumors.

Register To Buy and Sell Shares

For more details on financing and valuation for Pact Pharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Pact Pharma’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Pact Pharma.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Alex Franzusoff Ph.D
Chief Scientific Officer
Antoni Ribas Ph.D
Scientific Co-Founder & Board Member
Timothy Moore
Chief Technical Officer & President
Juan Jaen Ph.D
Co-Founder & Board Member
James Heath Ph.D
Scientific Co-Founder & Board Member
David Baltimore Ph.D
Scientific Co-Founder & Chairman of Scientific Advisory Board
Terry Rosen Ph.D
Co-Founder & Board Member
Blake Byers Ph.D
Interim President & Board Member

Board Members

Antoni Ribas Ph.D
Juan Jaen Ph.D
Terry Rosen Ph.D
David Baltimore Ph.D
James Heath Ph.D
Blake Byers Ph.D
KT Moortgat Ph.D
AbbVie Ventures

News Highlights

PACT Pharma Secures $75M in Series C Financing | FinSMEs
PACT Pharma, a SouthSan Francisco, Calif.-based advancing personalized NeoTCR-T cell therapies to eradicate solid tumors, closed a $75m Series C financing
VC-backed PACT Pharma taps Moore as president and CTO | PE Hub
South San Francisco-based PACT Pharma, a provider of personalized cell therapy for solid tumors, has appointed Tim Moore as president and chief technical officer. Previously, Moore worked at Kite where he was executive vice president of technical operations. PACT Pharma's backers included GV, Canaan, Casdin Capital, Droia, Foresite Capital, Invus, Pontifax, Wu Capital, AbbVie Ventures and Taiho Ventures.
Updated on: Feb 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.